Effect of angiotensin-converting enzyme inhibitors on anemia and erythropoietin requirements in hemodialysis patients
10.3760/cma.j.issn.1673-4904.2011.19.008
- VernacularTitle:血管紧张素转换酶抑制剂对血液透析患者贫血和促红细胞生成素用量的影响
- Author:
Xiaoshi ZHONG
;
Danping QIN
;
Xiao XIAO
;
Yan LIU
- Publication Type:Journal Article
- Keywords:
Angiotensin-converting enzyme inhibitors;
Erythropeietin;
Anemia;
Renal dialysis
- From:
Chinese Journal of Postgraduates of Medicine
2011;34(19):23-26
- CountryChina
- Language:Chinese
-
Abstract:
Objective To observe the effect of angiotensin-converting enzyme inhibitors (ACEI) on anemia and erythropoietin (EPO) requirements in maintenance hemodialysis patients. Methods Ninety maintenance hemodialysis patients with hypertension and anemia were divided into 2 groups by random digits table, observation group (45 cases, using ACEI as antihypertensive treatment), control group [45 cases,using calcium channel blocker (CCB) as antihypertensive treatment]. The follow-up period after starting ACEI or CCB therapy was one year. The hemoglobin concentration, serum EPO, EPO requirements were compared after 0, 2, 4, 6, 8, 10, 12 months' treatment. Results In response to ACEI, the mean hemoglobin value in observation group decreased progressively, reaching statistical significance after 6 months, and it had significant difference compared with that in control group [6 months: (94.21±9.20) g/Lvs. (105.55±9.16) g/L,12 months: (95.90±6.75) g/L vs. (105.81±4.45) g/L,P <0.05]. The EPO requirements experienced a progressive increase in observation group and reached statistical significance after 8 months, compared with those in control group [8 months: ( 10 090.75±1918.35) U/week vs. (7010.32±1600.15) U/week, 12 months: (11 586.39±2009.76) U/week vs. (7068.48±1615.35) U/week,P<0.05].Serum erythropoietin concentration remained stable during the study in two groups. Conclusion ACEI can worsen anemia and reduce the efficacy of EPO in maintenance hemodialysis patients.
